This episode of the CCI Deep Dive Podcast examines one of the most aggressively marketed—and most misunderstood—areas in regenerative medicine: umbilical cord, amniotic, and placental “stem cell” products. Drawing from published scientific investigations, the discussion breaks down why many of these birth-derived products do not contain functional living stem cells despite bold clinical claims. The episode walks listeners through the hard data, the extremely low viability rates (35–75%)...
All content for Centeno-Schultz Clinic - Podcasts is the property of Centeno-Schultz Clinic Staff and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode of the CCI Deep Dive Podcast examines one of the most aggressively marketed—and most misunderstood—areas in regenerative medicine: umbilical cord, amniotic, and placental “stem cell” products. Drawing from published scientific investigations, the discussion breaks down why many of these birth-derived products do not contain functional living stem cells despite bold clinical claims. The episode walks listeners through the hard data, the extremely low viability rates (35–75%)...
In this episode of CCI Deep Dive, Dr. Centeno unpacks the anatomy and meaning of a retroflexed dens—a common but often misunderstood MRI finding at the top of the neck. Learn why this structural variation is usually harmless, how it can become problematic when paired with craniocervical instability, and how advanced nonsurgical treatments like the PICL and ePIC procedures use your body’s own cells to restore stability. A clear, practical breakdown for anyone navigating complex CCI repor...
Centeno-Schultz Clinic - Podcasts
This episode of the CCI Deep Dive Podcast examines one of the most aggressively marketed—and most misunderstood—areas in regenerative medicine: umbilical cord, amniotic, and placental “stem cell” products. Drawing from published scientific investigations, the discussion breaks down why many of these birth-derived products do not contain functional living stem cells despite bold clinical claims. The episode walks listeners through the hard data, the extremely low viability rates (35–75%)...
